Subcutaneous versus intraperitoneal insulin for patients with diabetes mellitus on continuous ambulatory peritoneal dialysis: Meta-analysis of non-randomized clinical trials.
Diabetes mellitus remains the leading cause of end-stage renal disease (ESRD) worldwide and, in Canada, accounts for about 35% of new ESRD cases [1] . Adequate glycemic control in diabetic patients is necessary to further reduce morbidity in subjects with diabetes mellitus and ESRD [2] .
Hemodialysis (HD) and peritoneal dialysis (PD) are the main forms of replacement therapy in patients with ESRD. Selection between these methods is based on a number of factors including availability and convenience, co-morbid conditions, socioeconomic and dialysis center factors, residual renal function, the level of home support available [3] and patient preference. Although the percentage of patients undergoing HD far exceeds those being maintained on PD [1] , PD has some advantages over HD, including steady-state hemodynamics and biochemistry due to daily exchanges, simplicity of the technique, reduced cardiovascular stress, maintenance of optimal blood pressure and volume control [4] . Insulin can also be given in the dialysate in patients on PD rather than via multiple SC injections. PD can be performed either continuously over 24 hours using continuous ambulatory peritoneal dialysis (CAPD) or via automated devices at night known as nocturnal intermittent peritoneal dialysis (NIPD) or continuous cycling peritoneal dialysis (CCPD) [5] . Unlike patients on CAPD, intraperitoneal insulin (IP) is not o en used on CCPD patients due to a greater risk of nocturnal hypoglycemia and uncertainty in insulin dosing [6] . CAPD patients are dialyzed with conventional glucose-containing PD solutions, and the glucose that di uses into the patients' circulation leads to further risk of poor glycemic control. When insulin is administered through the IP route, most of the absorbed insulin is taken up by the portal venous system and delivered directly to the liver, which helps to create a portal-peripheral insulin gradient close to normal [7] and this may result in an improvement in insulin sensitivity [8] . When comparing IP insulin with conventional subcutaneous insulin regimens in patients on CAPD, several potential bene ts have been proposed with the IP route including better glycemic control with favorable HbA1C and lower rates of hypoglycemia with IP insulin. ere are also some possible drawbacks to IP insulin relative to the SC route including higher insulin requirements, lower HDL cholesterol levels and higher TG levels. e increased insulin requirement using the IP route is related to several factors including hepatic insulin degradation as in physiological circumstances, incomplete peritoneal absorption of insulin (which is concentration-and time-dependent), possible intraperitoneal degradation of insulin by insulinase enzymes, degradation within adipocytes and adsorption of insulin to the surface of uid containers and connecting tubing [9] . Several studies have suggested that the IP administration of insulin can restore glucose levels to near normal values [10] , but the available evidence is limited either because only a small number of subjects were used or because glycemic control was not the primary outcome. Many observational studies showed positive e ects, but observational studies cannot replace randomized trials. As few non-randomized controlled trials comparing IP and SC insulin are available, conducting a meta-analysis using the available data to increase the power of the current studies would help guide health practitioners in choosing IP insulin versus SC insulin in patients with diabetes mellitus on insulin on peritoneal dialysis.
Materials and Methods
e study was conducted to assess safety and e cacy of IP insulin administration in diabetic patients on PD as measured by HbA 1C as the primary outcome, with secondary outcomes including HDL, Apo-A1, triglycerides, the insulin dose requirement/day, and the risk of peritonitis and hepatic subcapsular steatosis.
Study eligibility
Studies were eligible if they were randomized or nonrandomized trials comparing IP insulin versus SC insulin in PD patients who were18 years of age and older with either type 1 or type 2 diabetes mellitus. Studies were excluded if they 1) had no comparison group, 2) were reports only of single cases, 3) did not focus on patients with ESRD or 4) used insulin analogues.
Search strategy
e following databases were searched: Medline (1950 to present with daily update), the EMBASE database from (1980 till February 2012) and Cochrane Database of Systematic Reviews 2005 to January 2012, using word elements: diabetes, peritoneal dialysis, insulin administration, and glucose control (Appendices 1-5). e reference lists of the extracted studies were also reviewed to identify references not appearing in the database searches. Unpublished trials and conference abstracts were not included. For trials with duplicate publications, the most complete and/or more recent publication was eligible for consideration and, where possible, for trials with incomplete or missing data, the author was contacted.
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Data Abstraction
Two reviewers (M.H.A and M.S.A) independently reviewed all the titles, abstracts and keywords of all recorded studied. Discordant results were resolved by a third reviewer (M.A.A). e data were extracted from the included studies using a standardized extraction form. Data abstracted were age, percentage of male and female study participants, sample size, type of study, duration of diabetes and follow-up period, mode PD, outcomes, main results and variables included in the adjusted model or models.
Statistical analysis
e results were analyzed by using RevMan, version 5.0. For pooling of the results from the three articles included in this systematic review, the standard error of the mean of all the study and outcome variables that were reported in these articles were used. From the standard error, the standard deviation (SD) and variance were derived. As the outcome variables HbA1C level, insulin level, HDL level and TG level are continuous measures, the standardized mean di erence (SMD) was used as the e ect size. Statistical heterogeneity was assessed and, based on its signi cance, either xed e ect models or random e ect models E ect size (SMD) was used appropriately to infer the results.
Pooled results are expressed as weighted mean di erences ( xed e ects model) if studies are clinically homogeneous and there 95% CIs for continuous outcomes. Clinical heterogeneity was observed in some of the outcomes; thus, a randome ects model was used. Heterogeneity was assessed using Isquared statistics with signi cance set at P < 0.10.
e Isquared statistic, ranging from 0 to 100%, measures the amount of variation between di erent studies that is due to heterogeneity. Values over 50% indicate a large degree of heterogeneity [11] . I2 can be estimated, along with its con dence intervals, and the con dence intervals are wider when a metaanalysis includes few studies.
uality assessment uality of the included studies was assessed using McMaster Critical Review Form-uantitative Studies [12] . Sixteen characteristics were assessed: study purpose; relevant background literature; design; sample description; whether sample size was Almalki et al. Intraperitoneal Insulin Use in Peritoneal Dialysis justi ed; whether outcome measures were reliable and valid; whether intervention was described; whether contamination and co-intervention were avoided; whether the results were reported in terms of signi cance; whether the analysis method(s) was/were appropriate; whether clinical importance and dropouts were reported; and whether the conclusions were appropriate given the study methods and results. Each characteristic was awarded a score of one. Two independent reviewers assessed the trials (M.H.A, M.S.A) and disagreement was resolved through discussion with third reviewer (M.A.A). Some characteristics were not applicable to all studies and hence the overall quality score varied (Appendix 6).
Results
e initial search (Fig. 1) yielded 21 studies. A er review of the abstracts, 18 studies were excluded: one was a duplicate publication [13] , three were review articles [14] [15] [16] , one used oral hypoglycemic agent but no insulin [17] , four did not involve patients on dialysis [18] [19] [20] [21] , one studied patients on nighttime IPD [22] , one used analogue insulin on non-dialysis subjects [23] , two studies had no comparison group [24, 25] , two were case reports [26, 27] and two did not contain adequate information (no HbA1C) [10] .
e rst author /corresponding author of one study [28] was contacted for additional data, but the database was no longer available. One study included nondiabetic patients [29] . Ultimately, only three non-randomized controlled trials were appropriate for inclusion in the metaanalysis [8, 30, 31] (Fig. 1) . All three had study populations including patients who had long-standing diabetes and who were treated with insulin.
Demographics e three trials involved 29 participants, all with type 1 diabetes mellitus. e mean age was 42.6 ± 3.1 years. Diabetes duration was 30 ± 3.2 years. Trial duration ranged from 3 to 6 months. During the subcutaneous insulin phase, the insulin was given either as multiple daily injections (MDI) or through an insulin pump. A er switching to IP insulin, patients injected regular insulin into the dialysis bags four times per day prior to uid exchange. ree of these daily doses were equal but the nightly dose was reduced by 20%. Insulin was titrated whenever necessary. Table 1 summaries the characteristics of the trials included in the review.
E ect of insulin route of administration on HbA1C
In non-randomized studies of diabetic patient on PD, glycemic control with IP insulin treatment, as assessed with HbA 1C , was better than that obtained with SC insulin [8, 9, 19, 30] . e analysis of the results of three studies showed that the HbA 1C was -1.49 % lower in the IP group (SMD -1.49 % CI -2.17 to -0.27, p=0.0001) with no heterogeneity (0=0.80 and I2= 0%). (Fig. 2 
E ect of insulin route of administration on daily insulin dose
e change from SC to IP insulin therapy resulted in an increase in insulin dose of more than two-fold in the IP group as compared with the SC group. When the data from the three studies was combined, the mean insulin dose was higher with IP insulin treatment than with SC insulin, with the pooled SMD in insulin dose (units per day) being 54.02 (95% C.I: 40.10 to 67.94). e test for heterogeneity was not statistically signi cant (p=0.91) and I2 = 0%. (Fig. 3) It is important to recognize that both the insulin dose and HbA1C may be a ected by patient weight. e change in the subject weight before and a er insulin administration in di erent phases was not reported, thus potentially a ecting both total daily insulin with IP route and HbA 1C results secondary to increased insulin resistance with weight gain. is could bias the noted signi cant di erence between di erent routes of administration.
E ect of insulin route of administration on other metabolic parameters
Serum HDL-cholesterol was lower with IP insulin therapy then with SC therapy (SMD -0.38; 95% CI:-p=0.00001). As low HDL levels are considered a cardiovascular risk factor, this di erence would favor SC insulin administration and was not related to patient heterogeneity (p =0.87 and I2 = 0%). (Fig. 4 Serum TG concentration tended to be lower during SC insulin as compared with IP insulin. Analysis of the results of three studies showed that the pooled SMD was 0.36 (95% CI: -0.13 to 0.84, p=0.15). is trend was not related to patient heterogeneity (p=0.99 mI2 = 0%). As high triglycerides are potentially deleterious to the vasculature, this di erence also favors SC insulin administration. (Fig. 5) LDL-cholesterol was evaluated in three trials, although but actual data was reported in only two [8, 31] , and showed a modest increase in LDL cholesterol in the IP group (not statistically signi cant). Apo lipoprotein A-1 and B did not change signi cantly during the study period in either study [8, 17] e rates of peritonitis events, hepatic subcapsular steatosis and hypoglycemia are important safety outcomes that may be increased in patients using IP insulin relative to those on SC insulin, and were unfortunately not reported in selected studies.
Discussion
is meta-analysis of three clinical trials of subjects with type 1 diabetes has shown that HbA 1C is improved in patients on IP insulin relative to those on SC insulin. As daily insulin doses di er with the two routes of administration, it cannot be determined with con dence whether the change in HbA 1C is related to the altered route of administration or to the higher insulin dose used in the IP patients. While this is useful information, it is important to note that there are no studies in the PD population that address the relationship between HbA 1C and cardiovascular outcomes.
Of note, the HbA 1C may overestimate glycemic control in patients with ESRD on replacement therapy due to the presence of hemoglobin like carbamylated hemoglobin [32] . Using HbA 1C assays with higher speci city for glycated hemoglobin may be a more precise monitoring tool for such patients.
In this review, the e ect of IP insulin on serum lipids was reported in three trials. Decreased HDL-cholesterol has been reported during IP insulin therapy in all studies, along with slight decrease in ApoA-1 in one study [31] . ere was a modest increase in TG a er switching from SC to IP insulin, which was consistent in all studies. It has been suggested that IP insulin enhances triglyceride synthesis by a direct action on the liver rather than by inhibiting the removal of TG [21] .
A slight increase in LDL-cholesterol occurred during CAPD while continuing on IP insulin. Mild increases in serum Apo-B were noted during the IP insulin period, but these changes were not statistically signi cant. It is not clear whether these lipoprotein abnormalities in patients receiving IP insulin would translate into additional risk for cardiovascular disease.
Moreover, there is no evidence that an improvement in the lipid parameters could lead to an improvement in the cardiovascular outcomes.
Safety issues are of concern with IP insulin. Although there is a potential risk of peritonitis, this has not been a consistent nding in clinical trials. In one study [4] of 11 patients, one episode of peritonitis was recorded during IP insulin treatment. In another study [28] of 30 patients, the incidence of peritonitis was four-fold greater in the IP group.
None of the selected studies reported hepatic subcapsular steatosis, but this condition has been reported in patients receiving IP during CAPD [33] [34] [35] . e impact of these potential safety concerns on patient survival is unknown and warrants further study. Unfortunately, the trials meeting the criteria for this Meta analysis did not report safety parameters and further data are needed to fully de ne the risks of the IP insulin approach.
e potential limitation of this review is that all trials were non-randomized. In addition, most trials were of short duration and small subject numbers, which could limit assessment of long-term safety and e cacy of IP insulin versus SC insulin: assessment for heterogeneity was used to attempt to control for this. Unpublished trials were not included in this study; hence, publication bias may be a limitation to the ndings of this study.
Conclusions
IP insulin results in improved HbA 1C relative to SC insulin but has some deleterious e ects on other metabolic parameters such as HDL and TG. e impact of IP insulin on peritonitis rates and hepatic subcapsular steatosis is not well de ned. Long-term e cacy and safety trials are required to see if improvement in the glycemic control noted when PD patients are switched from SC to IP insulin translates into a reduction in diabetes related and cardiovascular morbidity. It is clear that more information on this important topic is needed given that the prevalence of diabetes in the ESRF population is 40% and PD usage accounts for 30-50% of renal replacement therapy. 
